Kolltan Pharmaceuticals Licenses Novel anti-KIT Antibodies and Related …4-traders (press release)Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of To…
Kolltan Pharmaceuticals Licenses Novel anti-KIT Antibodies and Related …Business Wire (press release)BUSINESS WIRE)–Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with …
Spectrum Pharmaceuticals Highlights 13 Abstracts at the 55th Annual Meeting of …Wall Street Journal8, Autologous Stem Cell Transplantation (ASCT) In 6:30 PM-8:30 PM Patients With Germinal Center B (GCB) and Non- GCB Cell-Like Diffuse Large Hall G …
Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research – Zacks …NASDAQThe company has collaborations with companies like Roche (Rituxan), Acorda (Fampyra), Biovitrum (Eloctate and Alprolix) and AbbVie (daclizumab) among others. In ter…
Visterra acquires license for dengue antibodiesVaccine News DailyVisterra, Inc., an antibody therapeutics developer, announced on Monday that it secured an exclusive patent license to a family of early-stage monoclonal antibodies that target dengue vir…
MedPage TodayMorning Break: Radioactive Robbers, NYC E-Cig BanMedPage Today… Society of America has released a new practice guideline on vaccinations for immunodeficient patients. Example: flu shots are probably worthless in patients undergoing inten…
Pharmaceutical Processing |
Alvotech Invests $250M in Biopharmaceuticals
Pharmaceutical Processing Alvotech today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech’s current biosimilar assets include follow-on versions of leading monoclonal antibodies molecules … Alvogen Pumping $250M into Developing Biosimilars, with New Iceland PlantGenetic Engineering News Alvotech Invests $250 Million in BiopharmaceuticalsPharmiWeb.com (press release) |
Pharmaceutical Processing |
Alvotech to invests $250M in the development of biosimilar monoclonal antibodies
News-Medical.net Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech’s current biosimilar assets include … Alvotech Invests $250 Million in BiopharmaceuticalsBusiness Wire (press release) Alvotech Invests $250M in BiopharmaceuticalsPharmaceutical Processing Alvogen Pumping $250M into Developing Biosimilars, with New Iceland PlantGenetic Engineering News |
OncLive |
ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib
OncLive In this phase I study being presented by Anas Younes, MD, from MSKCC, the combination of first-line ibrutinib and rituximab (R)-CHOP was explored in treatment-naive patients with CD20-positive B-cell non-Hodgkin’s lymphoma (abstract 852). According to … |
Medical Marketing and Media |
Analyst: Don’t underestimate AbbVie
Medical Marketing and Media Rubin pointed out that the MS drug daclizumab, which is being developed with Biogen Idec, has safety and tolerability issues that undercut its efficacy profile. Rubin said heat surrounding new oral agents “with less safety concerns,” limit the … |